EPO and infection: Globally, the prevalence of HCV infection among dialysis patients has also shown a declining trend attributed to the availability of erythropoietin-stimulating agents, reduction in transfusions, increased infection control measures, routine serological screening, and the introduction of direct-acting antivirals for HCV treatment15,16.